Prism Medico & Pharmacy has scheduled a meeting of its Board of Directors for Monday, August 24, 2026. The session is set to begin at 1:00 pm at the company’s registered office in Sirmaur, Himachal Pradesh.

The primary agenda includes considering and approving the Director’s Report along with all necessary annexures for the financial year ended March 31, 2026. This approval is a prerequisite for the company to announce its annual financial results.

Key Agenda Items

Beyond the financial approvals, the board will address several corporate governance matters:

• Fixing the day, date, and time for the 24th Annual General Meeting (AGM) and approving the notice.
• Determining the closure dates for the Register of Members and Share Transfer Books for the AGM.
• Appointing a scrutinizer to conduct the e-voting and poll process for the upcoming AGM.

Auditor Appointments

The meeting will also focus on auditor appointments for the coming years:

• Statutory Auditors: The board will consider recommending the re-appointment of M/s. Garg Mendiratta and Associates as statutory auditors and fix their remuneration.
• Secretarial Auditors: The board will consider recommending the appointment of M/s. SDK & Associates as secretarial auditors for five financial years, from FY27 to FY31.

The intimation was issued in compliance with Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Prism Medico & Pharmacy Limited reported a net loss of ₹5.83 lakh for the first quarter of FY27 (Q1FY27), ending June 30, 2026, compared to a net profit of ₹65.73 lakh in Q1FY26. The Board of Directors approved the unaudited standalone financial results on August 12, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by Garg Mendiratta & Associates, the statutory auditors.

The company recorded zero revenue from operations in Q1FY27, a sharp contrast to the ₹158.87 lakh generated in the same quarter last year and ₹28.14 lakh in the immediately preceding quarter (Q4FY26). Total income for the quarter was ₹9.06 lakh, derived entirely from other income, which rose significantly from ₹0.04 lakh in Q1FY25. This lack of operational revenue highlights a potential pause or seasonal fluctuation in core business activities during the period.

Total expenses for the quarter amounted to ₹14.89 lakh, up from ₹93.84 lakh in Q1FY25 but higher than the ₹40.64 lakh seen in Q4FY26. Employee benefit expenses accounted for ₹1.77 lakh, while other expenses constituted the largest portion at ₹13.02 lakh. Finance costs remained negligible at ₹0.02 lakh, and depreciation and amortization expenses were ₹0.09 lakh. The profit before tax stood at a loss of ₹5.83 lakh, with no current or deferred tax expenses recorded for the quarter.

What the Numbers Show

The most striking feature of the Q1FY27 results is the complete absence of revenue from operations, which had been ₹158.87 lakh in the same quarter last year. While total expenses decreased substantially year-on-year due to lower material consumption (which was nil in both Q1FY27 and Q4FY26), the fixed costs such as employee benefits and other expenses continued to accrue. The shift from a net profit position in Q1FY26 to a net loss in Q1FY27 underscores the impact of the revenue gap. Additionally, paid-up equity share capital increased to ₹1,356.34 lakh from ₹606.34 lakh in previous periods, indicating a recent capital raise or bonus issue that has not yet translated into operational revenue generation in this quarter.